temozolomide has been researched along with Pheochromocytoma in 8 studies
Pheochromocytoma: A usually benign, well-encapsulated, lobular, vascular tumor of chromaffin tissue of the ADRENAL MEDULLA or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of EPINEPHRINE and NOREPINEPHRINE, is HYPERTENSION, which may be persistent or intermittent. During severe attacks, there may be HEADACHE; SWEATING, palpitation, apprehension, TREMOR; PALLOR or FLUSHING of the face, NAUSEA and VOMITING, pain in the CHEST and ABDOMEN, and paresthesias of the extremities. The incidence of malignancy is as low as 5% but the pathologic distinction between benign and malignant pheochromocytomas is not clear. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1298)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with temozolomide and thalidomide was associated with an objective biochemical (chromogranin A) response rate of 40%, and a radiologic response rate of 25% (45% among pancreatic endocrine tumors, 33% among pheochromocytomas, and 7% among carcinoid tumors)." | 9.12 | Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. ( Clark, JW; Enzinger, PC; Fuchs, CS; Kulke, MH; Michelini, A; Muzikansky, A; Ryan, DP; Stuart, K; Vincitore, M, 2006) |
| "Cyclophosphamide-dacarbazine-vincristine regimen is recommended for the treatment of malignant pheochromocytoma and paraganglioma (MPP); however, dacarbazine is the only recognized active drug in neuroendocrine tumours." | 7.80 | SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. ( Al Ghuzlan, A; Amar, L; Baudin, E; Bertherat, J; Borget, I; Caramella, C; Chougnet, C; Déandreis, D; Deschamps, F; Dumont, F; Favier, J; Gimenez-Roqueplo, AP; Hadoux, J; Leboulleux, S; Letouzé, E; Libé, R; Loriot, C; Schlumberger, M; Scoazec, JY; Young, J, 2014) |
| "Temozolomide (TMZ) has been shown to determine radiological and biochemical response in malignant PCC/PGLs." | 5.48 | Temozolomide treatment of a malignant pheochromocytoma and an unresectable MAX-related paraganglioma. ( Bertorelle, R; Ferrara, AM; Iacobone, M; Lombardi, G; Meringolo, D; Nardin, M; Opocher, G; Pambuku, A; Schiavi, F; Zagonel, V; Zovato, S, 2018) |
| "Treatment with temozolomide and thalidomide was associated with an objective biochemical (chromogranin A) response rate of 40%, and a radiologic response rate of 25% (45% among pancreatic endocrine tumors, 33% among pheochromocytomas, and 7% among carcinoid tumors)." | 5.12 | Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. ( Clark, JW; Enzinger, PC; Fuchs, CS; Kulke, MH; Michelini, A; Muzikansky, A; Ryan, DP; Stuart, K; Vincitore, M, 2006) |
| "The therapeutic options for metastatic pheochromocytomas/paragangliomas (mPPGLs) include chemotherapy with cyclophosphamide/vincristine/dacarbazine (CVD), temozolomide monotherapy, radionuclide therapies, and tyrosine kinase inhibitors such as sunitinib." | 4.31 | Responses to systemic therapy in metastatic pheochromocytoma/paraganglioma: a retrospective multicenter cohort study. ( Auernhammer, CJ; Bechmann, N; Beuschlein, F; Bornstein, SR; Dischinger, U; Fischer, A; Fliedner, SMJ; Grossman, AB; Hantel, C; Kloos, S; Kroiss, M; Maurer, J; Mohr, H; Nölting, S; Pacak, K; Pamporaki, C; Pellegata, NS; Reincke, M; Remde, H; Reul, A; Robledo, M; Timmers, HJLM; Wang, K, 2023) |
| "Cyclophosphamide-dacarbazine-vincristine regimen is recommended for the treatment of malignant pheochromocytoma and paraganglioma (MPP); however, dacarbazine is the only recognized active drug in neuroendocrine tumours." | 3.80 | SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. ( Al Ghuzlan, A; Amar, L; Baudin, E; Bertherat, J; Borget, I; Caramella, C; Chougnet, C; Déandreis, D; Deschamps, F; Dumont, F; Favier, J; Gimenez-Roqueplo, AP; Hadoux, J; Leboulleux, S; Letouzé, E; Libé, R; Loriot, C; Schlumberger, M; Scoazec, JY; Young, J, 2014) |
| " We investigated the effect of LB1, a small molecule inhibitor of serine/threonine protein phosphatase 2A (PP2A), on its ability to inhibit a low growth fraction and highly drug-resistant solid neuroendocrine tumor, such as metastatic pheochromocytoma (PHEO)." | 3.77 | Pharmacologic modulation of serine/threonine phosphorylation highly sensitizes PHEO in a MPC cell and mouse model to conventional chemotherapy. ( Bernardo, M; Chiang, J; Lonser, R; Lu, J; Martiniova, L; Pacak, K; Zhuang, Z, 2011) |
| "Temozolomide (TMZ) has been shown to determine radiological and biochemical response in malignant PCC/PGLs." | 1.48 | Temozolomide treatment of a malignant pheochromocytoma and an unresectable MAX-related paraganglioma. ( Bertorelle, R; Ferrara, AM; Iacobone, M; Lombardi, G; Meringolo, D; Nardin, M; Opocher, G; Pambuku, A; Schiavi, F; Zagonel, V; Zovato, S, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 4 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Perez, K | 1 |
| Jacene, H | 1 |
| Hornick, JL | 1 |
| Ma, C | 1 |
| Vaz, N | 1 |
| Brais, LK | 1 |
| Alexander, H | 1 |
| Baddoo, W | 1 |
| Astone, K | 1 |
| Esplin, ED | 1 |
| Garcia, J | 1 |
| Halperin, DM | 1 |
| Kulke, MH | 2 |
| Chan, JA | 1 |
| Wang, K | 2 |
| Crona, J | 1 |
| Beuschlein, F | 2 |
| Grossman, AB | 2 |
| Pacak, K | 3 |
| Nölting, S | 2 |
| Urquhart, C | 3 |
| Fleming, B | 3 |
| Harper, I | 3 |
| Aloj, L | 3 |
| Armstrong, R | 3 |
| Hook, L | 3 |
| Long, AM | 3 |
| Jackson, C | 3 |
| Gallagher, FA | 3 |
| McLean, MA | 3 |
| Tarpey, P | 3 |
| Kosmoliaptsis, V | 3 |
| Nicholson, J | 3 |
| Hendriks, AEJ | 3 |
| Casey, RT | 3 |
| Fischer, A | 1 |
| Kloos, S | 1 |
| Remde, H | 1 |
| Dischinger, U | 1 |
| Pamporaki, C | 1 |
| Timmers, HJLM | 1 |
| Robledo, M | 1 |
| Fliedner, SMJ | 1 |
| Maurer, J | 1 |
| Reul, A | 1 |
| Bechmann, N | 1 |
| Hantel, C | 1 |
| Mohr, H | 1 |
| Pellegata, NS | 1 |
| Bornstein, SR | 1 |
| Kroiss, M | 1 |
| Auernhammer, CJ | 1 |
| Reincke, M | 1 |
| Ferrara, AM | 1 |
| Lombardi, G | 1 |
| Pambuku, A | 1 |
| Meringolo, D | 1 |
| Bertorelle, R | 1 |
| Nardin, M | 1 |
| Schiavi, F | 1 |
| Iacobone, M | 1 |
| Opocher, G | 1 |
| Zagonel, V | 1 |
| Zovato, S | 1 |
| Hadoux, J | 1 |
| Favier, J | 1 |
| Scoazec, JY | 1 |
| Leboulleux, S | 1 |
| Al Ghuzlan, A | 1 |
| Caramella, C | 1 |
| Déandreis, D | 1 |
| Borget, I | 1 |
| Loriot, C | 1 |
| Chougnet, C | 1 |
| Letouzé, E | 1 |
| Young, J | 1 |
| Amar, L | 1 |
| Bertherat, J | 1 |
| Libé, R | 1 |
| Dumont, F | 1 |
| Deschamps, F | 1 |
| Schlumberger, M | 1 |
| Gimenez-Roqueplo, AP | 1 |
| Baudin, E | 1 |
| Martiniova, L | 1 |
| Lu, J | 1 |
| Chiang, J | 1 |
| Bernardo, M | 1 |
| Lonser, R | 1 |
| Zhuang, Z | 1 |
| Stuart, K | 1 |
| Enzinger, PC | 1 |
| Ryan, DP | 1 |
| Clark, JW | 1 |
| Muzikansky, A | 1 |
| Vincitore, M | 1 |
| Michelini, A | 1 |
| Fuchs, CS | 1 |
2 reviews available for temozolomide and Pheochromocytoma
| Article | Year |
|---|---|
Targeted Therapies in Pheochromocytoma and Paraganglioma.
Topics: Adrenal Gland Neoplasms; Humans; Paraganglioma; Pheochromocytoma; Randomized Controlled Trials as To | 2022 |
The use of temozolomide in paediatric metastatic phaeochromocytoma/paraganglioma: A case report and literature review.
Topics: Adrenal Gland Neoplasms; Adult; Brain Neoplasms; Child; Female; Humans; Neoplasms, Second Primary; P | 2022 |
The use of temozolomide in paediatric metastatic phaeochromocytoma/paraganglioma: A case report and literature review.
Topics: Adrenal Gland Neoplasms; Adult; Brain Neoplasms; Child; Female; Humans; Neoplasms, Second Primary; P | 2022 |
The use of temozolomide in paediatric metastatic phaeochromocytoma/paraganglioma: A case report and literature review.
Topics: Adrenal Gland Neoplasms; Adult; Brain Neoplasms; Child; Female; Humans; Neoplasms, Second Primary; P | 2022 |
The use of temozolomide in paediatric metastatic phaeochromocytoma/paraganglioma: A case report and literature review.
Topics: Adrenal Gland Neoplasms; Adult; Brain Neoplasms; Child; Female; Humans; Neoplasms, Second Primary; P | 2022 |
1 trial available for temozolomide and Pheochromocytoma
| Article | Year |
|---|---|
Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; An | 2006 |
5 other studies available for temozolomide and Pheochromocytoma
| Article | Year |
|---|---|
SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma.
Topics: Adrenal Gland Neoplasms; Humans; Mutation; Paraganglioma; Pheochromocytoma; Retrospective Studies; S | 2022 |
Responses to systemic therapy in metastatic pheochromocytoma/paraganglioma: a retrospective multicenter cohort study.
Topics: Adrenal Gland Neoplasms; Brain Neoplasms; Cardiovascular Diseases; Cohort Studies; Humans; Iodine Ra | 2023 |
Temozolomide treatment of a malignant pheochromocytoma and an unresectable MAX-related paraganglioma.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents, Alkylating; Basic Helix-Loop-Helix Leucine Zipper Tr | 2018 |
SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarke | 2014 |
Pharmacologic modulation of serine/threonine phosphorylation highly sensitizes PHEO in a MPC cell and mouse model to conventional chemotherapy.
Topics: Adrenal Gland Neoplasms; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; | 2011 |